Siebert, N.; Zumpe, M.; Schwencke, C.H.; Biskupski, S.; Troschke-Meurer, S.; Leopold, J.; Zikoridse, A.; Lode, H.N.
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers 2023, 15, 3317.
https://doi.org/10.3390/cancers15133317
AMA Style
Siebert N, Zumpe M, Schwencke CH, Biskupski S, Troschke-Meurer S, Leopold J, Zikoridse A, Lode HN.
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers. 2023; 15(13):3317.
https://doi.org/10.3390/cancers15133317
Chicago/Turabian Style
Siebert, Nikolai, Maxi Zumpe, Christian Heinrich Schwencke, Simon Biskupski, Sascha Troschke-Meurer, Justus Leopold, Alexander Zikoridse, and Holger N. Lode.
2023. "Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta" Cancers 15, no. 13: 3317.
https://doi.org/10.3390/cancers15133317
APA Style
Siebert, N., Zumpe, M., Schwencke, C. H., Biskupski, S., Troschke-Meurer, S., Leopold, J., Zikoridse, A., & Lode, H. N.
(2023). Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers, 15(13), 3317.
https://doi.org/10.3390/cancers15133317